**CPO20190050** is an **OXA-23-producing *Acinetobacter baumannii*** strain from Denmark isolated in 2019

**Sequence type**:
ST423 (Oxford)
ST2 (Pasteur)

**Genotype:**

| Antimicrobial agent | Resistance gene/mutations |
|---|---|
| Carbapenems | *bla* $_{\text{OXA-23}}$ |
| Third generation cephalosporins | *bla* $_{\text{PER-1}}$ |
| Other beta-lactams | *bla* $_{\text{ADC-25}}$, *bla* $_{\text{OXA-66}}$ |
| Colistin | Not detected |
| Fluoroquinolones | Not detected |
| Aminoglycosides | *aac(3)-Ia, aph(3'')-Ib, aph(3')-VIb, aph(6)-Id* |
| Tetracyclines | Not detected |
| Trimethoprim | Not detected |
| Sulphonamide | *sul2* |
| Fosfomycin | Not detected |

**Phenotype:**

| Antimicrobial agent | Reference MIC (mg/L) | Reference inhibition zone (mm)[1] | Interpretation[2] | WT/NWT[3] |
|---|---|---|---|---|
| Cefiderocol | ND | 6 | ND[4] | NWT |
| Imipenem | >16 | 6 | R | NWT |
| Meropenem | >16 | 6 | R | NWT |
| Ciprofloxacin | >4 | 6 | R | NWT |
| Levofloxacin | >2 | 6-9 | R | NWT |
| Amikacin | >64 | 10-13 | R | NWT |
| Gentamicin | >16 | 6-9 | R | NWT |
| Tobramycin | 2-4 | 17-20 | S | WT |
| Tigecycline | 0.5-1 | - | ND[5] | ECOFF NA |
| Colistin | 0.5 | - | S | WT |
| Trimethoprim-sulfamethoxazole | >16 | 6 | R | NWT |

ND: not determined; NA: not available.

[1]Using EUCAST disk diffusion methodology (https://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology)

[2]SIR-categorization according to The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0, 2025. https://www.eucast.org.

[3]Categorization into wild type (WT) or non-wild type (NWT) according to available epidemiological cut-off values (ECOFF) available at https://mic.eucast.org/

[4]Acinetobacter spp. with zone diameter <17 mm will likely be clinically resistant

[5]Interpretative criteria have not been established

Report created: **2025-Sep-29**